Roche is paying $1.65 billion in confirmed upfront fees to add to its burgeoning obesity pipelin | Roche is paying $1.65 ...
Roche is expanding its scope to a promising but competitive new obesity target, committing $1.65 billion up front to partner on a clinical-stage Zealand Pharma molecule with the potential to be a ...
Novo Nordisk announced disappointing data from a phase III study on a novel obesity candidate, CagriSema. Roche announced a ...
Basel: Roche has announced that it has entered into an exclusive collaboration and licensing agreement with Zealand Pharma.